Clinical efficacy of camrelizumab combined with lunvatinib or bevacizumab in the treatment of hepatocellular carcinoma

Abstract

Objective To evaluate the clinical efficacy of camrelizumab combined with lunvatinib or bevacizumab in the treatment of hepatocellular carcinoma （HCC）. Methods Clinical data of 60 patients with HCC were retrospectively analyzed. All patients were divided into group A （camrelizumab combined with lunvatinib） and group B （camrelizumab combined with bevacizumab）. Short-term clinical efficacy and the expression levels of serum tumor markers （alpha-fetoprotein，carcinoembryonic antigen，neuron-specific enolase，cytokeratin 19 fragment），matrix metalloproteinase-9 （MMP-9） and vascular endothelial growth factor （VEGF） were compared between two groups. The degree of cancer-related fatigue （CRF） before treatment was compared between two groups by using CRF scale. The incidence of adverse reactions，progression-free survival （PFS） and overall survival （OS） during the treatment were analyzed between two groups. Results No significant differences were observed in the short-term clinical efficacy，incidence of adverse reactions，PFS and OS between two groups （all P > 0.05）. After treatment，the expression levels of serum tumor markers，MMP-9，VEGF and CRF scores in two group were significantly lower than those before treatment，and the values in group B were lower than those in group A （all P < 0.05）. Conclusions No significant difference is observed in the clinical efficacy between camrelizumab combined with lunvatinib or bevacizumab in the treatment of HCC patients. However，combined use of camrelizumab and bevacizumab can significantly lower the expression levels of serum tumor markers，MMP-9 and VEGF and mitigate CRF in HCC patients.

Keywords

• |hepatocellular carcinoma|camrelizumab|bevaczumab|lunvatinib|tumor marker